Viatris Inc. (VTRS)
Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges
VTRS Q4 earnings and sales miss estimates. The guidance for 2025 looks disappointing due to the financial impact of the Indore facility warning letter and import alert.
Viatris Stock Tumbles On Q4 Earnings Miss, FDA Warning Clouds 2025 Outlook
On Thursday, Viatris Inc. VTRS reported fourth-quarter 2024 sales of $3.52 billion, down 8% year over year, missing the consensus of $3.61 billion.
Viatris Inc. (VTRS) Q4 2024 Earnings Call Transcript
Viatris Inc. (NASDAQ:VTRS ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Corinne Le Goff - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Ashwani Verma - UBS Chris Schott - JPMorgan Jason Gerberry - Bank of America Umer Raffat - Evercore Balaji Prasad - Barclays Operator Good morning everyone and welcome to the Viatris Q4 and Full Year 2024 Earnings Call. All participants will be in the listen-only mode.
Viatris: One Swallow Doesn't Make A Summer
Viatris Inc. missed estimates on sales and earnings per share. The company's 2025 guidance reveals significant challenges, including a $385 million EBITDA hit from issues at the Indore plant. We would stay out of VTRS stock.
Viatris Misses Estimates, Cash Flow Up
Viatris (VTRS -16.15%), a global healthcare company known for its broad portfolio of pharmaceutical products, released its fourth-quarter 2024 results on Feb. 27. Despite achieving substantial debt reduction and strategic advancements, Viatris fell short of analysts' forecasts.
Viatris (VTRS) Q4 Earnings and Revenues Lag Estimates
Viatris (VTRS) came out with quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.61 per share a year ago.
Drugmaker Viatris forecasts weak 2025 results after import curbs on India plant
Viatris forecast annual revenue and profit below Wall Street estimates on Thursday, two months after the U.S. health regulator restricted imports from one of the drugmaker's key plants in India.
Stay Ahead of the Game With Viatris (VTRS) Q4 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top -and-bottom-line estimates for Viatris (VTRS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
What's in the Cards for Viatris Stock This Q4 Earnings?
VTRS' Q4 results are likely to gain from new product launches in all major geographies.
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out
Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of "Phase 1" of its business transformation, and initiation of "Phase 2" of their strategic plan — returning to growth. Viatris markets a mix of generic and established brand drugs, with the latter's revenues declining due to patent expiries and market competition.
Is Viatris (VTRS) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
